Ocgn Phase 3 Results Date. 07 expected by the market 3 days ago · Each trial result is a po
07 expected by the market 3 days ago · Each trial result is a potential game-changer. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy January 15, 2026 8:30 AM ESTCompany Jan 15, 2026 · Has Ocugen received FDA approval? Track FDA approvals, PDUFA dates, and regulatory milestones for OCGN with the latest event history at MarketBeat. OCU400 is intended for the treatment of early Find the latest Cassava Sciences, Inc. Third Quarter 2025 Financial Results With the recent $20 million financing in the third quarter, we expect our current cash position provides sufficient runway to operate through 2Q 2026. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. Apr 29, 2025 · MALVERN, Pa. This crucial step follows their pipeline expansion initiative from May 2022. Jun 18, 2025 · OCU410ST also received a Rare Pediatric Disease status and now heads towards a pivotal Phase 2/3 trial. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory Jan 13, 2026 · MALVERN, Pa. Nov 5, 2025 · Ocugen (NASDAQ: OCGN) provided a business update and reported third quarter 2025 results. , April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. MALVERN, Pa. He talked about Covaxin in a cnn interview last week. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to 3 days ago · Ocugen Provides Business Update with Third Quarter 2025 Financial Results Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) pr Nov 9, 2024 · Ocugen, Inc. m. Subsequently, the Company is expecting to expand the OCU400 Phase 3 clinical trial for LCA patients in the second half of 2024 based on Phase 1/2 study results in LCA patients and alignment with the FDA. The company plans to initiate OCU410ST Phase 2/3 trial for Stargardt disease by mid-2025 Mar 5, 2025 · Reached an alignment with FDA on Phase 2/3 pivotal confirmatory clinical trial for OCU410ST for Stargardt disease potentially expediting clinical development by two to three years Completed dosing in OCU410 Phase 2 ArMaDa clinical trial (N=51) for geographic atrophy (GA). Morgan 2026 Healthcare Conference OCGN Dec-29 3 days ago · Has Ocugen received FDA approval? Track FDA approvals, PDUFA dates, and regulatory milestones for OCGN with the latest event history at MarketBeat. May 9, 2025 · Ocugen (NASDAQ: OCGN) reported Q1 2025 financial results and provided updates on its gene therapy pipeline. Jun 23, 2025 · Phase 3-ready NeoCart® technology targets knee cartilage repair with breakthrough cell therapy approach. 50, raising $22. Don't just follow biotech trends – anticipate them. Across both Phase 1 and Phase 2 clinical trials, no OCU410-related serious adverse events have been reported. The company closed a $20M registered direct offering in August and would receive an additional $30M if warrants are fully exercised, and reported $32. Additionally, Ocugen is establishing a Good Manufacturing Sep 17, 2024 · Exciting advancements in gene therapy at Ocugen with Phase 3 trials for retinitis pigmentosa and FDA approval goal by 2026. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U. Comprehensive suite of tools for trading and investing in biotech stocks. Now what is happening is that they are waiting for a certain number of COVID cases among the trial participants 2 weeks or more Jan 16, 2026 · Ocugen, Inc. Ocugen Inc (OCGN) will release its next earnings report on Mar 27, 2026. Jan 15, 2026 · Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. (NASDAQ: OCGN) reported third-quarter 2025 financial results and provided an update on its advancing portfolio of late-stage gene therapies for inherited retinal 3 days ago · Has Ocugen received FDA approval? Track FDA approvals, PDUFA dates, and regulatory milestones for OCGN with the latest event history at MarketBeat. announced preliminary 12-month data from its phase 2 ArMaDa clinical trial for OCU410, a gene therapy for geographic atrophy. The randomized trial seeks to demonstrate NeoCart's superiority over existing treatments. Whether it's a Phase 3 triumph or an unexpected study termination, we've got you covered. Actually, even Bharat themselves can't know the date. S. 's Q3 2024 earnings conference call and updates on their clinical programs and financial results. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a positive 2-year safety and efficacy update for the Phase 1/2 OCU400 clinical trial.